866-997-4948(US-Canada Toll Free)

Soft Tissue Sarcoma - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Oct 2013

Category :

Oncology

No. of Pages : 218 Pages


Global Markets Directs, \'Soft Tissue Sarcoma Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Soft Tissue Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma. Soft Tissue Sarcoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Soft Tissue Sarcoma.
  • A review of the Soft Tissue Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Soft Tissue Sarcoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Soft Tissue Sarcoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Soft Tissue Sarcoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Content

Table of Contents 2
List of Tables 7
List of Figures 8

Introduction 9
Global Markets Direct Report Coverage 9
Soft Tissue Sarcoma Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Soft Tissue Sarcoma 11
Soft Tissue Sarcoma Therapeutics under Development by Companies 13
Soft Tissue Sarcoma Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Pre-Clinical Stage Products 20
Comparative Analysis 20
Soft Tissue Sarcoma Therapeutics - Products under Development by Companies 21
Soft Tissue Sarcoma Therapeutics - Products under Investigation by Universities/Institutes 23
Companies Involved in Soft Tissue Sarcoma Therapeutics Development 24
Amgen Inc. 24
AstraZeneca PLC 25
Eli Lilly and Company 26
Merck & Co., Inc. 27
Infinity Pharmaceuticals, Inc. 28
Novartis AG 29
Auxilium Pharmaceuticals, Inc. 30
Pfizer Inc. 31
Cell Therapeutics, Inc. 32
Exelixis, Inc. 33
Menarini Group 34
Bayer AG 35
EntreMed, Inc. 36
Oncolytics Biotech Inc. 37
ARQULE, INC 38
CytRx Corporation 39
Threshold Pharmaceuticals, Inc. 40
Nanobiotix 41
Morphotek, Inc. 42
GP Pharm, S.A. 43
MolMed S.p.A. 44
PharmaMar, S.A. 45
Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd. 46
Recombio SA 47
Polaris Group 48
Soft Tissue Sarcoma - Therapeutics Assessment 49
Assessment by Monotherapy Products 49
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
regorafenib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
sabarubicin - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
axitinib - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
cixutumumab - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
retaspimycin hydrochloride - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
cediranib maleate - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
collagenase clostridium histolyticum - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
brostallicin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
ridaforolimus - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
ENMD-2076 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
panobinostat - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
ganitumab - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
aldoxorubicin - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
aldoxorubicin - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
cabozantinib (s)-malate - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
NGR-hTNF - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
pelareorep - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
TH-302 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
MORAb-004 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
tivantinib - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
NBTXR-3 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Angiotensin 1-7 - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
trabectedin - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
trabectedin - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
TNF-PEG 20 - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
CGTG-102 - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
doxorubicin liposomal - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
KPT-330 - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
CBI-101 - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
Anlotinib Hydrochloride - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
N-glycolyl-GM3/Very Small Size Proteoliposome Vaccine - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
Soft Tissue Sarcoma Therapeutics - Drug Profile Updates 133
Soft Tissue Sarcoma Therapeutics - Discontinued Products 204
Soft Tissue Sarcoma Therapeutics - Dormant Products 205
Soft Tissue Sarcoma - Product Development Milestones 206
Featured News & Press Releases 206
Sep 30, 2013: CytRx’s New Aldoxorubicin Data Demonstrates Significant Advantages over Doxorubicin 206
Jul 31, 2013: Karyopharm Therapeutics Initiates a Phase 1b Food-Effect Clinical Trial With the Novel Oral Selective Inhibitor of Nuclear Export Selinexor in Patients With Advanced Sarcomas 208
Jul 01, 2013: Threshold Pharmaceuticals Announces Update on Its Phase 3 Trial in Soft Tissue Sarcoma 209
Jun 24, 2013: CytRx Reaches Enrollment Target In International Phase IIb Clinical Trial With Aldoxorubicin As First-line Treatment For Soft Tissue Sarcoma 209
Jun 03, 2013: Nanobiotix’s NBTXR3 Achieves Clinical Milestone Reaching Proof-of-concept In Phase I Trial Of Soft Tissue Sarcoma 210
May 16, 2013: PharmaMar To Present New Studies With Yondelis At ASCO 2013 211
May 06, 2013: CytRx Gets Recommendation From DSMC To Complete International Phase IIb Trial With Aldoxorubicin As First-line Treatment For Soft Tissue Sarcoma 213
May 06, 2013: EntreMed Receives Chinese Patent For ENMD-2076 214
May 02, 2013: AstraZeneca\'s Experimental Cancer Drug Cediranib Beneficial For Treatment Of Alveolar Soft Part Sarcoma, NIH Study Finds 214
Apr 23, 2013: CytRx Announces Agreement With FDA On Special Protocol Assessment For Phase III Study With Aldoxorubicin For Soft Tissue Sarcoma 215

Appendix 217
Methodology 217
Coverage 217
Secondary Research 217
Primary Research 217
Expert Panel Validation 217
Contact Us 218
Disclaimer 218

List of Table


Number of Products Under Development for Soft Tissue Sarcoma, H2 2013 11
Products under Development for Soft Tissue Sarcoma - Comparative Analysis, H2 2013 12
Number of Products under Development by Companies, H2 2013 14
Number of Products under Development by Companies, H2 2013 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2013 16
Comparative Analysis by Late Stage Development, H2 2013 17
Comparative Analysis by Mid Clinical Stage Development, H2 2013 18
Comparative Analysis by Early Clinical Stage Development, H2 2013 19
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 20
Products under Development by Companies, H2 2013 21
Products under Development by Companies, H2 2013 (Contd..1) 22
Products under Investigation by Universities/Institutes, H2 2013 23
Amgen Inc., H2 2013 24
AstraZeneca PLC, H2 2013 25
Eli Lilly and Company, H2 2013 26
Merck & Co., Inc., H2 2013 27
Infinity Pharmaceuticals, Inc., H2 2013 28
Novartis AG, H2 2013 29
Auxilium Pharmaceuticals, Inc., H2 2013 30
Pfizer Inc., H2 2013 31
Cell Therapeutics, Inc., H2 2013 32
Exelixis, Inc., H2 2013 33
Menarini Group, H2 2013 34
Bayer AG, H2 2013 35
EntreMed, Inc., H2 2013 36
Oncolytics Biotech Inc., H2 2013 37
ARQULE, INC, H2 2013 38
CytRx Corporation, H2 2013 39
Threshold Pharmaceuticals, Inc., H2 2013 40
Nanobiotix, H2 2013 41
Morphotek, Inc., H2 2013 42
GP Pharm, S.A., H2 2013 43
MolMed S.p.A., H2 2013 44
PharmaMar, S.A., H2 2013 45
Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd., H2 2013 46
Recombio SA, H2 2013 47
Polaris Group, H2 2013 48
Assessment by Monotherapy Products, H2 2013 49
Assessment by Stage and Route of Administration, H2 2013 51
Assessment by Stage and Molecule Type, H2 2013 53
Soft Tissue Sarcoma Therapeutics - Drug Profile Updates 133
Soft Tissue Sarcoma Therapeutics - Discontinued Products 204
Soft Tissue Sarcoma Therapeutics - Dormant Products 205

List of Chart


Number of Products under Development for Soft Tissue Sarcoma, H2 2013 11
Products under Development for Soft Tissue Sarcoma - Comparative Analysis, H2 2013 12
Products under Development by Companies, H2 2013 13
Products under Investigation by Universities/Institutes, H2 2013 16
Late Stage Products, H2 2013 17
Mid Clinical Stage Products, H2 2013 18
Early Clinical Stage Products, H2 2013 19
Pre-Clinical Stage Products, H2 2013 20
Assessment by Monotherapy Products, H2 2013 49
Assessment by Route of Administration, H2 2013 50
Assessment by Stage and Route of Administration, H2 2013 51
Assessment by Molecule Type, H2 2013 52
Assessment by Stage and Molecule Type, H2 2013 53

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *